http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2734178-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2015-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ee26ff44476ec45e93df9357c297c76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf01c742a5dd03b22cabbee6035d511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b754b9091ced7df0576213d9722c20e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2609d7af2299149e3f338913690d2c8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2752710b88845f841d800e2e18de2144 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e9e1669d526bce33d66c10243f84ed7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95160dc9ecce5d8383995d5efaca5fc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_199bd7f9e528b5293ac9b7816c81e7b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d84ff1bc19a2376780354f3ccf1698a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_119f3d87ce6a6a670667cf955bff6d92 |
| publicationDate | 2019-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2734178-T3 |
| titleOfInvention | Bispecific T lymphocyte activating antigen binding molecules |
| abstract | A bispecific T lymphocyte activating antigen binding molecule comprising a) a first Fab molecule that specifically binds to a first antigen; b) a second Fab molecule that specifically binds to a second antigen, and in which the variable domains VL and VH of the Fab light chain and the Fab heavy chain replace each other; c) a third Fab molecule that specifically binds to the first antigen; and d) an Fc domain composed of a first and a second subunit that may have stable association; wherein the first antigen is a target cell antigen and the second antigen is a T lymphocyte activating antigen, in particular CD3, more particularly CD3 epsilon; wherein the third Fab molecule in c) is identical to the first Fab molecule in a); wherein in the constant CL domain of the first Fab molecule in a) and the third Fab molecule in c) the amino acid at position 124 is replaced by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is replaced by arginine (R) or lysine (K) (numbering according to Kabat), and in which in the constant domain CH1 of the first Fab molecule in a) and the third Fab molecule in c) the amino acid in the position 147 is replaced by glutamic acid (E) (numbering according to the EU Kabat index) and the amino acid at position 213 is replaced by glutamic acid (E) (numbering according to the Kabat EU index); and in which the Fc domain is an Fc domain of IgG, and in which in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, generating from thus a protuberance within the CH3 domain of the first subunit that is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the bump within the CH3 domain of the first subunit is positionable; and wherein (i) the first Fab molecule in a) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule in b), and the second Fab molecule in b) and the third Fab molecule in c) each merge at the C end of the Fab heavy chain to the N end of one of the subunits of the Fc domain in d), or (ii) the second Fab molecule in b) it is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule in a), and the first Fab molecule in a) and the third Fab molecule in c) each merge at the C end of the Fab heavy chain to the N end of one of the subunits of the Fc domain in d). |
| priorityDate | 2014-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 236.